Developmental Therapeutics Research Program

发育治疗研究计划

• 批准号: 9923038
• 负责人: GLENN LIU
• 金额: $ 10.35万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9923038
• 关键词: Advanced Malignant Neoplasm; Antibodies; Applied Research; Award; Basic Science; Biological; Biological Assay; Biological Markers; Cancer Center; Cancer Patient; Childhood; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Comprehensive Cancer Center; Development; Developmental Therapeutics Program; Direct Costs; Disease; Dreams; Drug Targeting; Estrogen receptor positive; Funding; Goals; Head Cancer; Hematologic Neoplasms; Image; Immunotherapy; Individual; Industry Collaboration; Innovative Therapy; Intervention; Investigational Therapies; Laboratories; Lead; Malignant Neoplasms; Malignant neoplasm of prostate; Mission; Molecular; Molecular Target; Monitor; National Clinical Trials Network; Neck Cancer; Neoplasm Circulating Cells; New Agents; Outcome; Paper; Pathway interactions; Patient-Focused Outcomes; Patients; Peer Review; Peptides; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Preparation; Publications; Publishing; Rain; Reproduction spores; Research; Research Personnel; Resource Sharing; Schools; Science; Services; Signal Transduction; Solid Neoplasm; Source; Strategic Planning; Therapeutic; Therapeutic Agents; Therapeutic Human Experimentation; Time; Translating; Translational Research; Translations; United States National Institutes of Health; Work; anticancer research; base; biomarker development; biomarker discovery; cancer biomarkers; cancer cell; cancer clinical trial; cancer therapy; clinical translation; college; data resource; drug discovery; early phase clinical trial; effective therapy; first-in-human; improved; interdisciplinary approach; member; new therapeutic target; novel; novel therapeutics; peer; pre-clinical; predictive test; programs; research and development; resistance mechanism; response; small molecule; targeted agent; targeted cancer therapy; therapeutic biomarker; therapeutic development; treatment strategy; tumor immunology

UWCCC Developmental Therapeutics (DT) Program Summary Co-Leaders: Glenn Liu, Shigeki Miyamoto, and Jing Zhang PROJECT SUMMARY/ABSTRACT The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to improve cancer patient outcomes by discovering new targets, developing therapeutic agents and biomarkers, and translating this research into early phase clinical trials. The DT Program provides the translational direction not only for DT members, but for other programs within the UWCCC (e.g. GEM, VR, TM). Clinical trial data and resources inform our understanding of response and resistance mechanisms and enable the identification of new therapeutic targets and treatment strategies to improve clinical outcomes. The DT Program has 59 core members, representing 18 departments and 5 different schools/colleges. Research impacts of DT members are evidenced by research awards totaling over $22.5M in annual direct cost of peer-reviewed and non-peer reviewed funding (including $3.45M NCI, $6.2M cancer-related other NIH agencies, $4.97M peer-reviewed non-NIH sources, $7.9M non-peer reviewed funding) and a significant number of publications (1228 publications, 18% of which result from intra-programmatic collaboration and 24% from inter-programmatic work). A key component of the new UWCCC Strategic Operating Plan is to further strengthen and develop Innovative Therapies and Cancer Biomarkers. Consistent with this strategic goal, the thematic aims of the DT Program are to: 1) discover new molecular targets for cancer therapy; 2) develop new agents and biomarkers; and 3) translate new therapies and biomarkers into clinical trials. To achieve this goal, it is critical to have a very strong program that discovers, develops, and translates novel interventions and biomarkers. To this end, members of the DT Program come from basic science, applied science, and clinical departments. This program has expertise ranging from basic discovery (molecular pathways and targets), to development (drugs/assays/biomarkers), to early clinical translation application (Phase 1 clinical trials). Translational and clinical research DT program members apply intra- and inter-programmatic research discoveries in clinical trials, performing the majority of first-in-human or early phase clinical trials, while individual disease-specific research teams (Disease Oriented Teams) focus primarily on phase 2 and 3 studies. DT members lead or participate in all clinical research groups facilitating both translational and reverse-translational opportunities.

UWCCC发展治疗学（DT）项目概述